SL
BCAX

Siren LLC’s Bicara Therapeutics BCAX Stock Holding History

Siren LLC’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$166M Sell
5,602,970
-200,000
-3% -$4.46M 3.37% 7
2026
Q1 		$115M Buy
5,802,970
+586,001
+11% +$10.1M 3.2% 7
2025
Q4 		$87.8M Hold
5,216,969
– – 2.62% 8
2025
Q3 		$82.4M Hold
5,216,969
– – 3.22% 5
2025
Q2 		$48.5M Buy
5,216,969
+1,949,886
+60% +$23.2M 2.51% 6
2025
Q1 		$42.6M Sell
3,267,083
-5,744
-0.2% -$76.3K 2.4% 11
2024
Q4 		$57M Buy
3,272,827
+200,000
+7% +$4.16M 2.52% 7
2024
Q3 		$78.3M Buy
+3,072,827
New +$78.4M 3.91% 4

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Siren LLC's BCAX Position: Q2 2026 in Review

Siren LLC reduced its Bicara Therapeutics (BCAX) stake by 3.4% in Q2 2026, selling an estimated $4.46M and leaving 5,602,970 shares worth $166M. The position accounts for 3.37% of the portfolio, ranked #7.

Siren LLC first reported a position in BCAX in Q3 2024 and has held it in 8 quarters since. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Siren LLC held 5,602,970 shares of Bicara Therapeutics worth $166M as of Q2 2026.
  • Siren LLC sold 200,000 Bicara Therapeutics shares in Q2 2026, an estimated $4.46M.
  • Bicara Therapeutics made up 3.37% of Siren LLC's portfolio in Q2 2026, its #7 holding.
  • Siren LLC first reported a position in Bicara Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Siren LLC's 13F filing for Q2 2026, filed 13 Aug 2026.